Gene variation affects patients' response to Plavix

10/26/2010 | Yahoo!

U.S. researchers analyzed nine published studies and found that patients with a variation of the CYP2C19 gene who underwent heart surgery were less likely to benefit from Plavix, an anti-clotting drug from Bristol-Meyers Squibb and Sanofi-Aventis. They said a genetic test might help pinpoint patients who are most likely to respond to the treatment.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director of Accreditation
Meridian Health Plan
Detroit, MI
Stop Loss Sales Executive, (Southern Region)
Indigo Insurance Services
Multiple Locations, SL_Multiple Locations
Chief Executive Officer
Center for Improving Value in Healthcare
Denver, CO
Quality Program Manager II, State Programs
Tufts Health Plan
Watertown, MA
Senior director risk adjustor and coding doc
Novant Health
Charlotte, NC